Jim Simons
ACRS icon

Jim Simons’s Aclaris Therapeutics ACRS Stock Holding History

Jim Simons’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.88M Sell
502,631
-622,700
-55% -$2.1M ﹤0.01% 1932
2025
Q4 		$3.39M Sell
1,125,331
-494,400
-31% -$1.25M 0.01% 1568
2025
Q3 		$3.08M Buy
1,619,731
+154,953
+11% +$270K ﹤0.01% 1773
2025
Q2 		$2.08M Buy
1,464,778
+513,384
+54% +$695K ﹤0.01% 2083
2025
Q1 		$1.46M Buy
951,394
+100,875
+12% +$215K ﹤0.01% 2185
2024
Q4 		$2.11M Sell
850,519
-520,181
-38% -$1.29M ﹤0.01% 2014
2024
Q3 		$1.58M Buy
1,370,700
+448,500
+49% +$550K ﹤0.01% 2167
2024
Q2 		$1.01M Sell
922,200
-751,200
-45% -$883K ﹤0.01% 2304
2024
Q1 		$2.08M Sell
1,673,400
-73,032
-4% -$87.1K ﹤0.01% 2007
2023
Q4 		$1.83M Buy
1,746,432
+1,098,780
+170% +$3.35M ﹤0.01% 2008
2023
Q3 		$4.44M Sell
647,652
-321,900
-33% -$2.75M 0.01% 1381
2023
Q2 		$10.1M Sell
969,552
-282,600
-23% -$2.56M 0.01% 1023
2023
Q1 		$10.1M Buy
1,252,152
+130,400
+12% +$1.65M 0.01% 1080
2022
Q4 		$17.7M Sell
1,121,752
-63,426
-5% -$1.02M 0.02% 774
2022
Q3 		$18.7M Sell
1,185,178
-144,500
-11% -$2.28M 0.03% 715
2022
Q2 		$18.6M Sell
1,329,678
-127,900
-9% -$1.79M 0.02% 773
2022
Q1 		$25.1M Sell
1,457,578
-219,300
-13% -$2.99M 0.03% 640
2021
Q4 		$24.4M Sell
1,676,878
-344,000
-17% -$5.21M 0.03% 616
2021
Q3 		$36.4M Sell
2,020,878
-411,000
-17% -$6.59M 0.05% 409
2021
Q2 		$42.7M Sell
2,431,878
-554,600
-19% -$12.6M 0.05% 385
2021
Q1 		$75.3M Sell
2,986,478
-281,700
-9% -$5.51M 0.09% 229
2020
Q4 		$21.1M Sell
3,268,178
-165,212
-5% -$697K 0.02% 727
2020
Q3 		$8.82M Buy
3,433,390
+153,550
+5% +$344K 0.01% 1227
2020
Q2 		$5.31M Buy
3,279,840
+104,204
+3% +$140K ﹤0.01% 1612
2020
Q1 		$3.3M Buy
3,175,636
+393,339
+14% +$535K ﹤0.01% 1797
2019
Q4 		$5.26M Buy
2,782,297
+813,581
+41% +$1.35M ﹤0.01% 1819
2019
Q3 		$2.13M Buy
1,968,716
+1,269,136
+181% +$1.8M ﹤0.01% 2247
2019
Q2 		$1.53M Buy
699,580
+272,200
+64% +$1.48M ﹤0.01% 2485
2019
Q1 		$2.56M Buy
427,380
+331,700
+347% +$2.2M ﹤0.01% 2184
2018
Q4 		$707K Buy
+95,680
New +$986K ﹤0.01% 2728
2017
Q3 		– Sell
-28,900
Closed -$784K – 3174
2017
Q2 		$784K Sell
28,900
-59,179
-67% -$1.61M ﹤0.01% 2644
2017
Q1 		$2.63M Sell
88,079
-86,521
-50% -$2.49M ﹤0.01% 2092
2016
Q4 		$4.74M Buy
+174,600
New +$4.45M 0.01% 1702

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Jim Simons's ACRS Position: Q1 2026 in Review

Jim Simons reduced its Aclaris Therapeutics (ACRS) stake by 55% in Q1 2026, selling an estimated $2.1M and leaving 502,631 shares worth $1.88M. The position accounts for ﹤0.01% of the portfolio, ranked #1932.

Jim Simons first reported a position in ACRS in Q4 2016 and has held it in 33 quarters since. The position peaked at $75.3M in Q1 2021. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Jim Simons held 502,631 shares of Aclaris Therapeutics worth $1.88M as of Q1 2026.
  • Jim Simons sold 622,700 Aclaris Therapeutics shares in Q1 2026, an estimated $2.1M.
  • Aclaris Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #1932 holding.
  • Jim Simons first reported a position in Aclaris Therapeutics in Q4 2016 and has held it in 33 quarters since.
  • Jim Simons's Aclaris Therapeutics position peaked at $75.3M in Q1 2021.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.